Cargando…

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores

PromarkerD is a biomarker-based blood test that predicts kidney function decline in people with type 2 diabetes (T2D) who may otherwise be missed by current standard of care tests. This study examined the association between canagliflozin and change in PromarkerD score (Δ score) over a three-year pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Kirsten E., Bringans, Scott D., O’Neill, Ronan S., Lumbantobing, Tasha S. C., Lui, James K. C., Davis, Timothy M. E., Hansen, Michael K., Lipscombe, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179173/ https://www.ncbi.nlm.nih.gov/pubmed/37176686 http://dx.doi.org/10.3390/jcm12093247

Ejemplares similares

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020)

The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
por: Bringans, Scott, et al.
Publicado: (2020)

A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease
por: Bringans, Scott, et al.
Publicado: (2020)

Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis
por: Fusfeld, Lauren, et al.
Publicado: (2022)

Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
por: Bringans, Scott D., et al.
Publicado: (2017)

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
por: Nasiri-Ansari, Νarjes, et al.
Publicado: (2018)

Gene Validation and Remodelling Using Proteogenomics of Phytophthora cinnamomi, the Causal Agent of Dieback
por: Andronis, Christina E., et al.
Publicado: (2021)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Deep proteogenomics; high throughput gene validation by multidimensional liquid chromatography and mass spectrometry of proteins from the fungal wheat pathogen Stagonospora nodorum
por: Bringans, Scott, et al.
Publicado: (2009)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway
por: Zhang, Wanqiu, et al.
Publicado: (2023)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Patient profiling in diabetes and role of canagliflozin
por: Amblee, Ambika
Publicado: (2014)

Prolonged diabetic ketoacidosis associated with canagliflozin
por: Sloan, Gordon, et al.
Publicado: (2018)

Repurposing Canagliflozin to target brain aging
por: Jayarathne, Hashan, et al.
Publicado: (2023)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Shiba, Kumiko, et al.
Publicado: (2018)

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice
por: Zuo, Qingjuan, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
por: Yale, J-F, et al.
Publicado: (2013)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming, Joshua W, et al.
Publicado: (2015)

SUN-700 Fournier’s Gangrene and Diabetic Ketoacidosis Caused by Canagliflozin
por: Stamatiades, George Alexiades, et al.
Publicado: (2020)

Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
por: Hasan, Raquibul, et al.
Publicado: (2020)

Effects of canagliflozin on human myocardial redox signalling: clinical implications
por: Kondo, Hidekazu, et al.
Publicado: (2021)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2019)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway
por: Sun, Pengbo, et al.
Publicado: (2021)

Assessment of the quality of independent nursing practice in Indonesia based on total quality management indicators
por: Sahputra, Devi, et al.
Publicado: (2021)

Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014)

Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin
por: Kaur, Arshpreet, et al.
Publicado: (2015)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Canagliflozin-associated diabetic ketoacidosis: a case report
por: Chai, Peter R., et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
por: Adachi, Junichiro, et al.
Publicado: (2017)

Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin
por: Papadopoli, David, et al.
Publicado: (2021)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_esi3gsu8npmvrg80r6d50pg4gf